Extramedullary multiple myeloma
M Bhutani, DM Foureau, S Atrash, PM Voorhees… - Leukemia, 2020 - nature.com
Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma,
characterized by the ability of a subclone to thrive and grow independent of the bone …
characterized by the ability of a subclone to thrive and grow independent of the bone …
OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES
JK Choi, W ** of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working …
C Fernández de Larrea, RA Kyle, BGM Durie… - Leukemia, 2013 - nature.com
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by
the presence of circulating plasma cells. It is classified as either primary PCL occurring at …
the presence of circulating plasma cells. It is classified as either primary PCL occurring at …
[PDF][PDF] Guidelines for the diagnosis and management of multiple myeloma 2011.
JM Bird, RG Owen, S D'Sa, JA Snowden… - British journal of …, 2011 - iacld.com
1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …
Genetic aberrations and survival in plasma cell leukemia
RE Tiedemann, N Gonzalez-Paz, RA Kyle… - Leukemia, 2008 - nature.com
Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that
originates either as primary disease (pPCL) or as a secondary leukemic transformation …
originates either as primary disease (pPCL) or as a secondary leukemic transformation …
Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy
D Dingli, S Ailawadhi, PL Bergsagel, FK Buadi… - Mayo Clinic …, 2017 - Elsevier
Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …
an increasing number of novel agents with various mechanisms of action against the …
Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities
L Colomo, F Loong, S Rives, S Pittaluga… - The American journal …, 2004 - journals.lww.com
Plasmablastic lymphoma was initially described as a variant of diffuse large B-cell
lymphoma (DLBCL) involving the oral cavity of HIV+ patients and characterized by …
lymphoma (DLBCL) involving the oral cavity of HIV+ patients and characterized by …